Methods for treating circadian rhythm disorders
First Claim
1. A method for achieving a circadian rhythm phase-shifting effect in a human, the method comprising the step ofadministering to the human an amount of melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human, wherein said administration produces in the human a plasma melatonin or agonist concentration of greater than quiescent melatonin or equivalent agonist levels at a time that overlaps with either onset of endogenous melatonin production in the human or offset of endogenous melatonin production in the human, wherein when the circadian rhythm phase-shifting effect is a phase advance, melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human is administered at a time after about CT 6 and prior to CT 14 to produce plasma melatonin or agonist concentrations of greater than quiescent melatonin or equivalent agonist levels that overlap endogenous melatonin production onset, said greater than quiescent melatonin or equivalent agonist levels rise before the melatonin onset and fall after the melatonin onset;
- or wherein when the circadian rhythm phase-shifting effect is a phase delay, melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human is administered at a time after about CT 18 and prior to CT 1 to produce plasma melatonin or agonist concentration of greater than quiescent melatonin or equivalent agonist levels that overlaps offset of endogenous melatonin production, said greater than quiescent melatonin or equivalent agonist levels rise before the melatonin offset and fall after the melatonin offset.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for treating circadian rhythm disorders is described. The method involves the administration of melatonin, melatonin agonists or compounds that stimulate endogenous melatonin production so that the durations of the effective plasma concentrations of melatonin, melatonin agonists or compounds that stimulate endogenous melatonin production overlap with onset or offset of pre-treatment endogenous melatonin production, to provide a circadian-rhythm phase advance or phase delay, respectively. The methods of the invention also provide for concentration and/or duration of the effective plasma concentrations of melatonin, melatonin agonists or compounds that stimulate endogenous melatonin production to be greater in the time interval between about 8 hours before the dim light endogenous melatonin onset (DLMO) to about 4 hours after DLMO than in the time interval from about 4 hours after DLMO to about 8 hours before DLMO to achieve a circadian-rhythm phase advance. The methods of the invention also provide for concentration and/or duration of the effective plasma concentrations of melatonin, melatonin agonists or compounds that stimulate endogenous melatonin production to be greater in the time interval between about 4 hours after DLMO to about 8 hours before DLMO than in the time interval from about 8 hours before DLMO time to about 4 hours after DLMO to achieve a circadian-rhythm phase delay. In addition, the invention provides methods for regulating a human'"'"'s exposure to light and dark to prevent or enhance, respectively, the human'"'"'s endogenous production of melatonin. The use of melatonin antagonists, inverse agonists and melatonin inhibitory compounds such as beta-blockers for achieving a circadian-rhythm phase-shifting effect (opposite to that of melatonin administration) are also provided by the invention. The methods of the invention are illustrated by teachings for use of these methods for alleviating a variety of circadian rhythm-related disorders, including jet lag, winter depression, shift work-related desynchronies and sleep phase disorders.
49 Citations
10 Claims
-
1. A method for achieving a circadian rhythm phase-shifting effect in a human, the method comprising the step of
administering to the human an amount of melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human, wherein said administration produces in the human a plasma melatonin or agonist concentration of greater than quiescent melatonin or equivalent agonist levels at a time that overlaps with either onset of endogenous melatonin production in the human or offset of endogenous melatonin production in the human, wherein when the circadian rhythm phase-shifting effect is a phase advance, melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human is administered at a time after about CT 6 and prior to CT 14 to produce plasma melatonin or agonist concentrations of greater than quiescent melatonin or equivalent agonist levels that overlap endogenous melatonin production onset, said greater than quiescent melatonin or equivalent agonist levels rise before the melatonin onset and fall after the melatonin onset; - or
wherein when the circadian rhythm phase-shifting effect is a phase delay, melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human is administered at a time after about CT 18 and prior to CT 1 to produce plasma melatonin or agonist concentration of greater than quiescent melatonin or equivalent agonist levels that overlaps offset of endogenous melatonin production, said greater than quiescent melatonin or equivalent agonist levels rise before the melatonin offset and fall after the melatonin offset. - View Dependent Claims (2, 3, 4, 5, 6, 9, 10)
- or
- 7. A method for achieving a circadian rhythm phase-shifting effect in a human, the method comprising administering to the human an amount of melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human, wherein said administration produces in the human a plasma melatonin or agonist concentration of greater than quiescent melatonin or equivalent agonist levels for a time or in a concentration that is different during a time interval from about ct 6 to about ct 18 than that produced during the time interval from about CT 18 to about CT 6, wherein when the circadian rhythm phase-shifting effect is a phase advance, melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human is administered after about CT 6 and prior to CT 14, or when the circadian rhythm phase-shifting effect is a phase delay, melatonin, melatonin agonist or compound that increases endogenous production of melatonin in the human is administered after about CT 18 and prior to CT 1.
Specification